Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 26 May 2017 Planned End Date changed from 31 Oct 2018 to 30 Nov 2018.
- 28 Apr 2017 Planned End Date changed from 28 Jul 2018 to 31 Oct 2018.